Inhibikase Therapeutics

Inhibikase Therapeutics is a clinical-stage company developing small-molecule protein kinase inhibitors for neurodegenerative and cardiopulmonary diseases.

Their lead candidate, risvodetinib, is a selective, brain-penetrant c-Abl (Abelson tyrosine kinase) inhibitor for Parkinson’s disease. The goal is to slow or halt disease progression by targeting the underlying biological mechanism

They’re also exploring risvodetinib in Multiple System Atrophy (MSA), another alpha‑synuclein–driven neurodegenerative condition

Through their proprietary RAMP platform, they developed IkT‑001Pro, a prodrug of imatinib. It’s designed to deliver targeted Abl kinase inhibition more safely and tolerably for pulmonary arterial hypertension (PAH). Preclinical data shows reduced side effects compared to imatinib, and clinical development is advancing into late-stage trials